This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset

David Misdrahi, MDa,b,*; Arnaud Tessier, MSca,b; Joel Swendsen, PhDb; Fabrice Berna, MD, PhDa,c; Lore Brunel, MSca,d; Delphine Capdevielle, MD, PhDa,e; Isabelle Chereau, MDa,f; Jean-Marie Danion, MDa,c; Marie De Pradier, MDa,g; Jean-Michel Dorey, MDa,h; Caroline Dubertret, MD, PhDa,g; Julien Dubreucq, MDa,i; Catherine Faget, MDa,j; Franck Gabayet, MSca,i; Romain Rey, MDa,h; Raphaelle Richieri, MD, PhDa,j; Christine Passerieux, MD, PhDa,k; Aurélie Schandrin, MDa,e; Franck Schurhoff, MD, PhDa,d; Anne Marie Tronche, MDa,f; Mathieu Urbach, MDa,k; Pierre Michel Llorca, MD, PhDa,f; and Guillaume Fond, MDa,d; for the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groupl  

Published: September 28, 2016

Article Abstract

Objective: Medication nonadherence is one of the most important, and potentially modifiable, prognostic factors in the outcome of patients with schizophrenia. The aim of this article is to propose a new classification of adherence profiles according to the Medication Adherence Rating Scale (MARS) in a large community-dwelling sample of French patients with schizophrenia to provide a new tool to help clinicians in daily practice.

Methods: 319 community-dwelling patients from a national network of 10 Schizophrenia Expert Centers were interviewed between January 2009 and January 2014. Assessments were conducted with a dedicated electronic medical record including the Structured Clinical Interview for DSM-IV Disorders. A cluster analysis was performed to explore clinical variables associated with poor adherence.

Results: Two distinct groups of patients were identified relative to their main adherence style. Items about medications’ subjective negative effects constituted the greatest discriminating factor between the 2 clusters. Patients with poor adherence (n = 117) were significantly younger (adjusted OR [aOR] = 1.036; 95% CI, 1.004-1.069) and had higher levels of current depression (aOR = 0.894; 95% CI, 0.829-0.964) and lower insight (aOR = 0.820; 95% CI, 0.693-0.970).

Conclusions: The MARS provides a useful tool for clinicians and can also aid in the evaluation of adherence styles and their determinants in patients with schizophrenia. The element providing the greatest discriminative power between the 2 clusters was a subjective negative attitude toward medication. The findings also suggest that depression is more frequent in schizophrenia patients with poor adherence and that improving insight into illness might be suggested as a first-line intervention to improve adherence in this population.

Volume: 77

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF